Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2012 | 07:50pm CEST

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
05/25EISAI : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Provide Update on Supple..
AQ
05/25MERCK AND : Eisai And Merck Provide Update on Supplemental New Drug Application ..
AQ
05/25AstraZeneca cancer drug hits second goal by extending survival
RE
05/25MERCK AND : Eisai And Merck Provide Update on Supplemental New Drug Application ..
PR
05/25MERCK AND : Eisai and Merck Provide Update on Supplemental New Drug Application ..
PU
05/24MERCK AND : Announces Third-Quarter 2018 Dividend
AQ
05/24MERCK AND : KEYTRUDA Significantly Improved Overall Survival and Progression-Fre..
AQ
05/24Keytruda improves survival in first-line squamous NSCLC
AQ
05/23Why the world needs more than one Ebola vaccine
RE
05/23MERCK AND : KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival an..
BU
More news
News from SeekingAlpha
11:07aVENTURE CAPITAL DEALS OF THE WEEK : Ant Financial's $200M Motion Sensor Bet 
09:00aMINING ASCO 2018'S GOLD, PART 4 : Radiation Glows In Breast And Brain 
06:51aKnow When To Hold 'Em 
05/25Xeris Pharmaceuticals on deck for IPO 
05/253 THINGS IN BIOTECH, MAY 24 : Immunotherapy Makes Yet Another Foray 
Financials ($)
Sales 2018 42 112 M
EBIT 2018 13 641 M
Net income 2018 7 201 M
Debt 2018 15 704 M
Yield 2018 3,30%
P/E ratio 2018 22,70
P/E ratio 2019 15,24
EV / Sales 2018 4,15x
EV / Sales 2019 3,95x
Capitalization 159 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 69,1 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY5.01%158 970
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708
AMGEN2.33%117 942